...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Short telomere subtelomeric hypomethylation is associated with telomere attrition in elderly diabetic patients
【24h】

Short telomere subtelomeric hypomethylation is associated with telomere attrition in elderly diabetic patients

机译：短端粒体细胞尺寸低甲基化与老年糖尿病患者的端粒磨损有关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Telomere shortening is well known to be associated with the aging process and aging-associated diseases, including diabetes. The telomere length and subtelomeric methylation status in peripheral leucocytes (LTL) were compared in elderly type 2 diabetes (T2D) patients and diabetes-free controls (C). The methylation status was analyzed between MspI-TRF lengths and HpaII-TRF lengths by using methylation-sensitive and -insensitive restriction enzyme isoschizomers, MspI and HpaII, respectively. The mean telomere lengths, MspI-TRF or HpaII-TRF, were not significantly different between C and T2D patients. The percentage of fractionated densitometry showed that long and middle telomeres (>9.4 kb, 4.4-9.4 kb) were unaltered but short telomeres (<4.4 kb) in T2D patients were increased compared with C group. The methylation status revealed subtelomeric hypomethylation in short telomeres of T2D patients. When some patients with T2D were treated with 3-hydroxy-3-methylglutaril coenzyme A (HMG-CoA) reductase inhibitors (statin), results seen in short telomere of T2D patients were not observed and were not different from C. This suggested that this altered subtelomeric hypomethylation may be associated with the accelerated telomere shortening in elderly diabetic patients. These results also mean that the subtelomeric hypomethylation can also be influenced by statin treatment in T2D.
机译：众所周知，端粒缩短是与糖尿病在内的老化过程和衰老相关疾病有关。将外周白细胞（LT1）中的端粒长度和亚细节甲基化状态进行比较，患者2型糖尿病（T2D）患者和无糖尿病对照（C）进行比较。通过使用甲基化敏感和 - 敏感的限制酶异槐体，MSPI和HPAII分别在MSPI-TRF长度和HPAII-TRF长度之间分析甲基化状态。平均端粒长度，MSPI-TRF或HPAII-TRF在C和T2D患者之间没有显着差异。分级密度测定法的百分比显示，未妨碍长和中端粒（> 9.4kb，4.4-9.4kb），但与C组相比，T2D患者的短端粒（<4.4kb）增加。甲基化状态显示T2D患者短端粒体中的亚细胞尺寸低甲基化。当用3-羟基-3-甲基谷辅酶A（HMG-COA）还原酶抑制剂（他汀类药物）处理一些T2D患者时，未观察到T2D患者的短端粒体中所见的结果，并没有与C.这表明这一点改变的亚细胞尺寸低甲基化可以与老年人糖尿病患者的加速端粒缩短相关。这些结果也意味着亚细胞微调低甲基化也可以受到T2D中的特征治疗的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号